Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical company focused on developing and commercializing cardiovascular disease treatment technologies, including its BackBeat Cardiac Neuromodulation Therapy platform. The company reached public markets through a business combination with Health Assurance Acquisition Corp, a blank-check vehicle that completed its IPO in 2020 and was sponsored by Health Assurance Acquisition Corp LLC, a vehicle tied to healthcare industry executives including Evolent Health co-founders. The de-SPAC transaction ultimately resulted in the combined entity trading under the OBIO ticker on Nasdaq in the healthcare and medical devices sector. This 10-Q quarterly filing was submitted in May 2021. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on OBIO and hundreds of other SPAC transactions.